Opendata, web and dolomites

MetaTox-HS

Advanced Solutions for High Sensitivity Metabolism and Toxicity Assays

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaTox-HS project word cloud

Explore the words cloud of the MetaTox-HS project. It provides you a very rough idea of what is the project "MetaTox-HS" about.

boost    instrumentation    scoring    final    businesses    kits    cum    synergy    solution    highlights    electronic    labs    drug    industry    consolidating    flexible    ltd    sub    sole    laboratory    made    verification    commercial    creation    re    lux    toxicity    instruments    tests    hs    plan    challenger    few    models    pharmaceutical    polymer    innovative    opportunity    consumable    previously    passing    either    scientific    scientists    manufacturing    secures    party    disease    standard    job    stages    fluorescence    doxycheck    market    uhs    innovation    revenue    serious    position    nanosensor    14    completes    readiness    proof    engineering    critical    contract    bedside    bench    microfabrication    academia    review    biosciences    capex    components    clear    jobs    business    expensive    metatox    pilot    13    platform    cell    vivo    5m    enormous    est    beneficiary    write    prototyped    trade    submitted    reg    3rd    requirement    full       criteria    metabolism    luxcel    dominated    oct    mitoxpress    vitro    translate    accessible    2023    performance    16    reader    3bn    ambition    plate    demonstrated    320m    global    turnover   

Project "MetaTox-HS" data sheet

The following table provides information about the project.

Coordinator
LUXCEL BIOSCIENCES LTD 

Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL
city: Cork
postcode: T12
website: www.luxcel.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.agilent.com/en/metatox-hs
 Total cost 1˙469˙333 €
 EC max contribution 1˙028˙533 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUXCEL BIOSCIENCES LTD IE (Cork) coordinator 1˙028˙533.00

Map

 Project objective

'Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease, for researchers in academia, institutions and the pharmaceutical industry, that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.

Luxcel Biosciences Ltd (LUX) has prototyped innovation that can now bring these high performance tests, to all laboratory scientists, for use on standard laboratory instrumentation already available in est. 20,000 labs (fluorescence plate reader), without requirement for CapEx.

LUX’s business innovation solution is a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of LUX’s fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.

MetaTox-HS project, completes the final stages of development, verification, pilot process and manufacturing readiness, together with dissemination and exploitation activities, to bring the full product solution to market and secures EU based revenue and job creation; 13 new jobs and €14.5m cum turnover by 2023, consolidating LUXCEL’s EU position (2 YR), and ambition to become a serious #2 challenger in this est. €320m accessible US and global market (5 YR), currently dominated by US businesses.

Proposal previously submitted Oct ’16, scoring highly, passing all three criteria. Following a full commercial review LUXCEL has taken a sole beneficiary role, with key enabling technology provided through 3rd party sub-contract. A full re-write highlights: clear product components, demonstrated proof-of-concept, well-defined market opportunity and strong commercial plan to boost growth. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METATOX-HS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METATOX-HS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

NAS (2018)

Nexilis augmentation system

Read More